366 related articles for article (PubMed ID: 36050733)
1. Anthracycline-induced cardiotoxicity: targeting high-density lipoproteins to limit the damage?
Abrahams C; Woudberg NJ; Lecour S
Lipids Health Dis; 2022 Sep; 21(1):85. PubMed ID: 36050733
[TBL] [Abstract][Full Text] [Related]
2. Molecular mechanisms of doxorubicin-induced cardiotoxicity: novel roles of sirtuin 1-mediated signaling pathways.
Wang A J; Zhang J; Xiao M; Wang S; Wang B J; Guo Y; Tang Y; Gu J
Cell Mol Life Sci; 2021 Apr; 78(7):3105-3125. PubMed ID: 33438055
[TBL] [Abstract][Full Text] [Related]
3. Doxorubicin-induced cardiotoxicity is suppressed by estrous-staged treatment and exogenous 17β-estradiol in female tumor-bearing spontaneously hypertensive rats.
Pokrzywinski KL; Biel TG; Rosen ET; Bonanno JL; Aryal B; Mascia F; Moshkelani D; Mog S; Rao VA
Biol Sex Differ; 2018 Jun; 9(1):25. PubMed ID: 29907135
[TBL] [Abstract][Full Text] [Related]
4. Comparison of cardiac events associated with liposomal doxorubicin, epirubicin and doxorubicin in breast cancer: a Bayesian network meta-analysis.
Yamaguchi N; Fujii T; Aoi S; Kozuch PS; Hortobagyi GN; Blum RH
Eur J Cancer; 2015 Nov; 51(16):2314-20. PubMed ID: 26343314
[TBL] [Abstract][Full Text] [Related]
5. Anthracycline-Induced Cardiotoxicity: Causes, Mechanisms, and Prevention.
Bhagat A; Kleinerman ES
Adv Exp Med Biol; 2020; 1257():181-192. PubMed ID: 32483740
[TBL] [Abstract][Full Text] [Related]
6. Autophagy and mitophagy in the context of doxorubicin-induced cardiotoxicity.
Koleini N; Kardami E
Oncotarget; 2017 Jul; 8(28):46663-46680. PubMed ID: 28445146
[TBL] [Abstract][Full Text] [Related]
7. Protease-activated receptor 1 activation enhances doxorubicin-induced cardiotoxicity.
Antoniak S; Tatsumi K; Schmedes CM; Grover SP; Pawlinski R; Mackman N
J Mol Cell Cardiol; 2018 Sep; 122():80-87. PubMed ID: 30098988
[TBL] [Abstract][Full Text] [Related]
8. VEGF-B gene therapy inhibits doxorubicin-induced cardiotoxicity by endothelial protection.
Räsänen M; Degerman J; Nissinen TA; Miinalainen I; Kerkelä R; Siltanen A; Backman JT; Mervaala E; Hulmi JJ; Kivelä R; Alitalo K
Proc Natl Acad Sci U S A; 2016 Nov; 113(46):13144-13149. PubMed ID: 27799559
[TBL] [Abstract][Full Text] [Related]
9. Is there scope for better individualisation of anthracycline cancer chemotherapy?
Sallustio BC; Boddy AV
Br J Clin Pharmacol; 2021 Feb; 87(2):295-305. PubMed ID: 33118175
[TBL] [Abstract][Full Text] [Related]
10. Pathophysiology and preventive strategies of anthracycline-induced cardiotoxicity.
Chung WB; Youn HJ
Korean J Intern Med; 2016 Jul; 31(4):625-33. PubMed ID: 27378126
[TBL] [Abstract][Full Text] [Related]
11. Biomarkers for Presymptomatic Doxorubicin-Induced Cardiotoxicity in Breast Cancer Patients.
Todorova VK; Makhoul I; Siegel ER; Wei J; Stone A; Carter W; Beggs ML; Owen A; Klimberg VS
PLoS One; 2016; 11(8):e0160224. PubMed ID: 27490685
[TBL] [Abstract][Full Text] [Related]
12. Candidate early predictive plasma protein markers of doxorubicin-induced chronic cardiotoxicity in B6C3F
Desai VG; Lee T; Moland CL; Vijay V; Han T; Lewis SM; Herman EH; Fuscoe JC
Toxicol Appl Pharmacol; 2019 Jan; 363():164-173. PubMed ID: 30517846
[TBL] [Abstract][Full Text] [Related]
13. Dosing depending on SIRT3 activity attenuates doxorubicin-induced cardiotoxicity via elevated tolerance against mitochondrial dysfunction and oxidative stress.
Yang N; Ma H; Jiang Z; Niu L; Zhang X; Liu Y; Wang Y; Cheng S; Deng Y; Qi H; Wang Z
Biochem Biophys Res Commun; 2019 Sep; 517(1):111-117. PubMed ID: 31303273
[TBL] [Abstract][Full Text] [Related]
14. Immune response proteins as predictive biomarkers of doxorubicin-induced cardiotoxicity in breast cancer patients.
Yu LR; Cao Z; Makhoul I; Daniels JR; Klimberg S; Wei JY; Bai JP; Li J; Lathrop JT; Beger RD; Todorova VK
Exp Biol Med (Maywood); 2018 Feb; 243(3):248-255. PubMed ID: 29224368
[TBL] [Abstract][Full Text] [Related]
15. Pharmaceutical Measures to Prevent Doxorubicin-Induced Cardiotoxicity.
Liu H; Wang H; Xiang D; Guo W
Mini Rev Med Chem; 2017; 17(1):44-50. PubMed ID: 27337969
[TBL] [Abstract][Full Text] [Related]
16. Anthracycline-induced cardiotoxicity - are we about to clear this hurdle?
Dempke WCM; Zielinski R; Winkler C; Silberman S; Reuther S; Priebe W
Eur J Cancer; 2023 May; 185():94-104. PubMed ID: 36966697
[TBL] [Abstract][Full Text] [Related]
17. AMPK/PGC1α activation by melatonin attenuates acute doxorubicin cardiotoxicity via alleviating mitochondrial oxidative damage and apoptosis.
Liu D; Ma Z; Di S; Yang Y; Yang J; Xu L; Reiter RJ; Qiao S; Yuan J
Free Radic Biol Med; 2018 Dec; 129():59-72. PubMed ID: 30172748
[TBL] [Abstract][Full Text] [Related]
18. HDL protects against doxorubicin-induced cardiotoxicity in a scavenger receptor class B type 1-, PI3K-, and Akt-dependent manner.
Durham KK; Chathely KM; Mak KC; Momen A; Thomas CT; Zhao YY; MacDonald ME; Curtis JM; Husain M; Trigatti BL
Am J Physiol Heart Circ Physiol; 2018 Jan; 314(1):H31-H44. PubMed ID: 28986362
[TBL] [Abstract][Full Text] [Related]
19. Edaravone and benidipine protect myocardial damage by regulating mitochondrial stress, apoptosis signalling and cardiac biomarkers against doxorubicin-induced cardiotoxicity.
Hassan MQ; Akhtar MS; Afzal O; Hussain I; Akhtar M; Haque SE; Najmi AK
Clin Exp Hypertens; 2020 Jul; 42(5):381-392. PubMed ID: 31630586
[No Abstract] [Full Text] [Related]
20. Doxorubicin-induced cardiotoxicity: An update on the molecular mechanism and novel therapeutic strategies for effective management.
Rawat PS; Jaiswal A; Khurana A; Bhatti JS; Navik U
Biomed Pharmacother; 2021 Jul; 139():111708. PubMed ID: 34243633
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
